

Kathryn J Ruddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/621332/publications.pdf>

Version: 2024-02-01

179
papers

11,009
citations

50244

46
h-index

36008

97
g-index

181
all docs

181
docs citations

181
times ranked

15618
citing authors

#	ARTICLE	IF	CITATIONS
1	Breast cancer. Nature Reviews Disease Primers, 2019, 5, 66.	18.1	1,620
2	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	13.7	1,099
3	Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. Journal of Clinical Oncology, 2017, 35, 893-911.	0.8	860
4	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	2.6	711
5	Patient adherence and persistence with oral anticancer treatment. Ca-A Cancer Journal for Clinicians, 2009, 59, 56-66.	157.7	496
6	Prospective Study of Fertility Concerns and Preservation Strategies in Young Women With Breast Cancer. Journal of Clinical Oncology, 2014, 32, 1151-1156.	0.8	313
7	Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting. New England Journal of Medicine, 2016, 375, 134-142.	13.9	307
8	Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). Journal of Clinical Oncology, 2015, 33, 3416-3422.	0.8	216
9	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. European Heart Journal, 2022, 43, 280-299.	1.0	213
10	Ovarian reserve in women who remain premenopausal after chemotherapy for early stage breast cancer. Fertility and Sterility, 2010, 94, 638-644.	0.5	173
11	Risk of Heart Failure With Preserved Ejection Fraction in Older Women After Contemporary Radiotherapy for Breast Cancer. Circulation, 2017, 135, 1388-1396.	1.6	169
12	Emotional Problems, Quality of Life, and Symptom Burden in Patients With Lung Cancer. Clinical Lung Cancer, 2017, 18, 497-503.	1.1	165
13	Biology of premature ageing in survivors of cancer. ESMO Open, 2017, 2, e000250.	2.0	148
14	Management of Male Breast Cancer: ASCO Guideline. Journal of Clinical Oncology, 2020, 38, 1849-1863.	0.8	122
15	Breast cancer in adolescents and young adults. Pediatric Blood and Cancer, 2018, 65, e27397.	0.8	117
16	Survivorship, Version 2.2018, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2018, 16, 1216-1247.	2.3	113
17	Common Genetic Variation and Breast Cancer Risk—Past, Present, and Future. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 380-394.	1.1	108
18	<i>BRCA1</i> and <i>BRCA2</i> Mutation Testing in Young Women With Breast Cancer. JAMA Oncology, 2016, 2, 730.	3.4	105

#	ARTICLE	IF	CITATIONS
19	The Epidemiology of Male Breast Cancer. <i>Current Oncology Reports</i> , 2016, 18, 1.	1.8	100
20	Breast cancer presentation and diagnostic delays in young women. <i>Cancer</i> , 2014, 120, 20-25.	2.0	96
21	Treatment-related amenorrhea and sexual functioning in young breast cancer survivors. <i>Cancer</i> , 2014, 120, 2264-2271.	2.0	93
22	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. <i>Breast Cancer Research</i> , 2016, 18, 15.	2.2	88
23	National Cancer Institute-supported chemotherapy-induced peripheral neuropathy trials: outcomes and lessons. <i>Supportive Care in Cancer</i> , 2016, 24, 1439-1447.	1.0	86
24	Male breast cancer in the United States: Treatment patterns and prognostic factors in the 21st century. <i>Cancer</i> , 2020, 126, 26-36.	2.0	82
25	Local Therapy Decision-Making and Contralateral Prophylactic Mastectomy in Young Women with Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 3809-3815.	0.7	81
26	Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2017, 15, 1140-1163.	2.3	81
27	Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 2375-2385.	0.8	76
28	Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. <i>European Journal of Cancer</i> , 2019, 120, 20-30.	1.3	75
29	Pregnancy After Breast Cancer: A Systematic Review and Meta-Analysis. <i>Journal of Clinical Oncology</i> , 2021, 39, 3293-3305.	0.8	70
30	Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). <i>Supportive Care in Cancer</i> , 2016, 24, 5059-5068.	1.0	67
31	Partner support and anxiety in young women with breast cancer. <i>Psycho-Oncology</i> , 2015, 24, 1679-1685.	1.0	65
32	Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). <i>Breast Cancer Research and Treatment</i> , 2015, 151, 589-596.	1.1	65
33	NCCN Guidelines Insights: Survivorship, Version 2.2019. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 784-794.	2.3	65
34	Scrambler Therapy for the management of chronic pain. <i>Supportive Care in Cancer</i> , 2016, 24, 2807-2814.	1.0	64
35	Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1409-1418.	0.8	64
36	NCCN Guidelines Insights: Survivorship, Version 2.2020. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1016-1023.	2.3	64

#	ARTICLE	IF	CITATIONS
37	Sequencing of C-M-T ooth disease genes in a toxic polyneuropathy. <i>Annals of Neurology</i> , 2014, 76, 727-737.	2.8	63
38	A contemporary review of male breast cancer: current evidence and unanswered questions. <i>Cancer and Metastasis Reviews</i> , 2018, 37, 599-614.	2.7	63
39	NCCN Guidelines Insights: Survivorship, Version 1.2016. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2016, 14, 715-724.	2.3	62
40	Association of Breast Cancer Surgery With Quality of Life and Psychosocial Well-being in Young Breast Cancer Survivors. <i>JAMA Surgery</i> , 2020, 155, 1035.	2.2	62
41	Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. <i>JCO Oncology Practice</i> , 2021, 17, 305-313.	1.4	62
42	Menopausal symptoms and fertility concerns in premenopausal breast cancer survivors. <i>Menopause</i> , 2011, 18, 105-108.	0.8	60
43	Young Women with Breast Cancer: A Focus Group Study of Unmet Needs. <i>Journal of Adolescent and Young Adult Oncology</i> , 2013, 2, 153-160.	0.7	59
44	Patient-reported (EORTC QLQ-CIPN20) versus physician-reported (CTCAE) quantification of oxaliplatin- and paclitaxel/carboplatin-induced peripheral neuropathy in NCCTG/Alliance clinical trials. <i>Supportive Care in Cancer</i> , 2017, 25, 3537-3544.	1.0	52
45	E-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium. <i>Scientific Reports</i> , 2018, 8, 6574.	1.6	51
46	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. <i>Npj Breast Cancer</i> , 2020, 6, 4.	2.3	49
47	Testing of candidate single nucleotide variants associated with paclitaxel neuropathy in the trial NCCTG N08C1 (Alliance). <i>Cancer Medicine</i> , 2016, 5, 631-639.	1.3	48
48	Can pregabalin prevent paclitaxel-associated neuropathy? An ACCRU pilot trial. <i>Supportive Care in Cancer</i> , 2016, 24, 547-553.	1.0	47
49	Model Program to Improve Care for a Unique Cancer Population: Young Women With Breast Cancer. <i>Journal of Oncology Practice</i> , 2012, 8, e105-e110.	2.5	46
50	Oxybutynin vs Placebo for Hot Flashes in Women With or Without Breast Cancer: A Randomized, Double-Blind Clinical Trial (ACCRU SC-1603). <i>JNCI Cancer Spectrum</i> , 2020, 4, pkz088.	1.4	46
51	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 725-733.	0.8	46
52	A pilot study of minocycline for the prevention of paclitaxel-associated neuropathy: ACCRU study RU221408I. <i>Supportive Care in Cancer</i> , 2017, 25, 3407-3416.	1.0	45
53	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. <i>Journal of the National Cancer Institute</i> , 2021, 113, 329-337.	3.0	45
54	Study protocol for Young & Strong: a cluster randomized design to increase attention to unique issues faced by young women with newly diagnosed breast cancer. <i>BMC Public Health</i> , 2015, 15, 37.	1.2	41

#	ARTICLE	IF	CITATIONS
55	Fertility (male and female) and Menopause. <i>Journal of Clinical Oncology</i> , 2012, 30, 3705-3711.	0.8	40
56	Biomarker prediction of chemotherapy-related amenorrhea in premenopausal women with breast cancer participating in E5103. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 591-597.	1.1	40
57	Association of the Charcot-Marie-Tooth disease gene ARHGEF10 with paclitaxel induced peripheral neuropathy in NCCTG N08CA (Alliance). <i>Journal of the Neurological Sciences</i> , 2015, 357, 35-40.	0.3	40
58	Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor-Negative: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2021, 39, 3938-3958.	0.8	40
59	Association of Genomic Domains in <i>BRCA1</i> and <i>BRCA2</i> with Prostate Cancer Risk and Aggressiveness. <i>Cancer Research</i> , 2020, 80, 624-638.	0.4	39
60	Pseudohyperkalemia in Chronic Lymphocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2008, 26, 2781-2782.	0.8	37
61	Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. <i>Cancer</i> , 2019, 125, 3266-3274.	2.0	37
62	Laying to Rest Psychostimulants for Cancer-Related Fatigue?. <i>Journal of Clinical Oncology</i> , 2014, 32, 1865-1867.	0.8	36
63	Trajectories of fear of cancer recurrence in young breast cancer survivors. <i>Cancer</i> , 2022, 128, 335-343.	2.0	33
64	Randomized controlled trial of cryotherapy to prevent paclitaxel-induced peripheral neuropathy (RU221511I); an ACCRU trial. <i>Breast</i> , 2019, 48, 89-97.	0.9	32
65	Quality of life and symptoms in male breast cancer survivors. <i>Breast</i> , 2013, 22, 197-199.	0.9	30
66	Promoting Accrual of Older Patients with Cancer to Clinical Trials: An Alliance for Clinical Trials in Oncology Member Survey (A171602). <i>Oncologist</i> , 2018, 23, 1016-1023.	1.9	29
67	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021, 99, 102241.	3.4	29
68	Three-Fraction Intracavitary Accelerated Partial Breast Brachytherapy: Early Provider and Patient-Reported Outcomes of a Novel Regimen. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 104, 75-82.	0.4	27
69	Assessing Unmet Information Needs of Breast Cancer Survivors: Exploratory Study of Online Health Forums Using Text Classification and Retrieval. <i>JMIR Cancer</i> , 2018, 4, e10.	0.9	27
70	Integrative medicine in cancer survivors. <i>Current Opinion in Oncology</i> , 2017, 29, 235-242.	1.1	26
71	Incidence, Diagnosis, and Treatment of Cardiac Toxicity From Trastuzumab in Patients With Breast Cancer. <i>Current Breast Cancer Reports</i> , 2017, 9, 173-182.	0.5	26
72	Treatment of Nonmetastatic Breast Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1716.	3.8	26

#	ARTICLE	IF	CITATIONS
73	Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. <i>Breast Cancer Research and Treatment</i> , 2013, 141, 421-427.	1.1	25
74	Unique Aspects of Caring for Young Breast Cancer Patients. <i>Current Oncology Reports</i> , 2015, 17, 1.	1.8	25
75	Long-Term Risk Perceptions of Women With Ductal Carcinoma In Situ. <i>Oncologist</i> , 2013, 18, 362-368.	1.9	24
76	Symptom burden and integrative medicine in cancer survivorship. <i>Supportive Care in Cancer</i> , 2015, 23, 2989-2994.	1.0	23
77	3 fraction pencil-beam scanning proton accelerated partial breast irradiation: early provider and patient reported outcomes of a novel regimen. <i>Radiation Oncology</i> , 2019, 14, 211.	1.2	23
78	Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. <i>Cancer</i> , 2021, 127, 2888-2894.	2.0	23
79	<p>Risk factors for poor health-related quality of life in cancer survivors with multiple chronic conditions: exploring the role of treatment burden as a mediator</p>. <i>Patient Related Outcome Measures</i> , 2019, Volume 10, 89-99.	0.7	22
80	Employment trends in young women following a breast cancer diagnosis. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 207-214.	1.1	22
81	Risks of subsequent primary cancers among breast cancer survivors according to hormone receptor status. <i>Cancer</i> , 2021, 127, 3310-3324.	2.0	22
82	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 35, 23-32.	1.8	20
83	Exclusion of Male Patients in Breast Cancer Clinical Trials. <i>JNCI Cancer Spectrum</i> , 2018, 2, pky018.	1.4	20
84	Pregnancy after breast cancer: Results from a prospective cohort of young women with breast cancer. <i>Cancer</i> , 2021, 127, 1021-1028.	2.0	20
85	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2339-2348.	3.2	20
86	Molecular Phenotype of Breast Cancer According to Time Since Last Pregnancy in a Large Cohort of Young Women. <i>Oncologist</i> , 2015, 20, 713-718.	1.9	19
87	Pragmatic cluster randomized trial to evaluate effectiveness and implementation of enhanced EHR-facilitated cancer symptom control (E2C2). <i>Trials</i> , 2020, 21, 480.	0.7	19
88	Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). <i>Breast Cancer Research and Treatment</i> , 2021, 189, 103-110.	1.1	19
89	Spirituality and Emotional Distress Among Lung Cancer Survivors. <i>Clinical Lung Cancer</i> , 2019, 20, e661-e666.	1.1	18
90	Utilization of Cardiac Surveillance Tests in Survivors of Breast Cancer and Lymphoma After Anthracycline-Based Chemotherapy. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e005984.	0.9	18

#	ARTICLE	IF	CITATIONS
91	Out-of-Pocket Costs Among Patients With a New Cancer Diagnosis Enrolled in High-Deductible Health Plans vs Traditional Insurance. <i>JAMA Network Open</i> , 2021, 4, e2134282.	2.8	18
92	Extended Therapy With Letrozole and Ovarian Suppression in Premenopausal Patients With Breast Cancer After Tamoxifen. <i>Clinical Breast Cancer</i> , 2014, 14, 413-416.	1.1	16
93	A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 535-544.	1.1	16
94	Modifiable Risk Factors for the Development of Breast Cancer in Young Women. <i>Cancer Journal (Sudbury, Mass)</i> , 2018, 24, 275-284.	1.0	15
95	Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. <i>Psycho-Oncology</i> , 2019, 28, 1033-1040.	1.0	15
96	Individualizing Surveillance Mammography for Older Patients After Treatment for Early-Stage Breast Cancer. <i>JAMA Oncology</i> , 2021, 7, 609.	3.4	15
97	Management of Hormone Deprivation Symptoms After Cancer. <i>Mayo Clinic Proceedings</i> , 2016, 91, 1133-1146.	1.4	14
98	Alternative Exercise Traditions in Cancer Rehabilitation. <i>Physical Medicine and Rehabilitation Clinics of North America</i> , 2017, 28, 181-192.	0.7	14
99	Ultrasensitive Ultrasound Microvessel Imaging for Characterizing Benign and Malignant Breast Tumors. <i>Ultrasound in Medicine and Biology</i> , 2019, 45, 3128-3136.	0.7	14
100	Integrated Rehabilitation for Breast Cancer Survivors. <i>American Journal of Physical Medicine and Rehabilitation</i> , 2019, 98, 154-164.	0.7	14
101	Cardiovascular Health during and after Cancer Therapy. <i>Cancers</i> , 2020, 12, 3737.	1.7	14
102	Challenges in Treating Premenopausal Women with Endocrine-Sensitive Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, 23-32.	1.8	14
103	Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 677-683.	1.1	13
104	Ten-Year Trends in Antiemetic Prescribing in Patients Receiving Highly Emetogenic Chemotherapy. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018, 16, 294-299.	2.3	13
105	The impact of dependent coverage expansion under the Affordable Care Act on time to breast cancer treatment among young women. <i>PLoS ONE</i> , 2018, 13, e0198771.	1.1	13
106	ADEpedia-on-OHDSI: A next generation pharmacovigilance signal detection platform using the OHDSI common data model. <i>Journal of Biomedical Informatics</i> , 2019, 91, 103119.	2.5	13
107	Follow-up Care for Breast Cancer Survivors. <i>Journal of the National Cancer Institute</i> , 2020, 112, 111-113.	3.0	13
108	Partners of young breast cancer survivors: a cross-sectional evaluation of psychosocial concerns, coping, and mental health. <i>Journal of Psychosocial Oncology</i> , 2020, 38, 670-686.	0.6	13

#	ARTICLE	IF	CITATIONS
109	A qualitative exploration of supports and unmet needs of diverse young women with breast cancer. <i>Journal of Community and Supportive Oncology</i> , 2015, 13, 323-329.	0.1	13
110	Randomized phase 2 trial of a coordinated breast cancer follow-up care program. <i>Cancer</i> , 2016, 122, 3546-3554.	2.0	12
111	A randomized study to improve care for young women with breast cancer at community and academic medical oncology practices in the United States: The Young and Strong study. <i>Cancer</i> , 2019, 125, 1799-1806.	2.0	12
112	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 157-165.	1.1	12
113	A CNV-Distracton Paradigm in Combat Veterans With Posttraumatic Stress Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2004, 16, 102-108.	0.9	11
114	Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 1097-1101.	2.3	11
115	Novel approaches to support breast cancer survivorship care models. <i>Breast</i> , 2017, 36, 1-13.	0.9	11
116	Genetic Predictors of Chemotherapy-Induced Peripheral Neuropathy from Paclitaxel, Carboplatin and Oxaliplatin: NCCTG/Alliance N08C1, N08CA and N08CB Study. <i>Cancers</i> , 2021, 13, 1084.	1.7	11
117	Treatment-related amenorrhea in a modern, prospective cohort study of young women with breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 99.	2.3	11
118	Association of Uveitis and Macular Edema With Anastrozole Therapy. <i>JAMA Ophthalmology</i> , 2018, 136, 837.	1.4	10
119	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	0.5	10
120	Immune Responses and Risk of Triple-negative Breast Cancer: Implications for Higher Rates among African American Women. <i>Cancer Prevention Research</i> , 2020, 13, 901-910.	0.7	10
121	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. <i>JCO Oncology Practice</i> , 2022, 18, 211-216.	1.4	10
122	Pilot implementation to assess the feasibility and care team impact of an app-based interactive care plan to remotely monitor breast cancer survivors. <i>Journal of Cancer Survivorship</i> , 2022, 16, 13-23.	1.5	10
123	Body weight changes and associated predictors in a prospective cohort of young breast cancer survivors. <i>Cancer</i> , 2022, 128, 3158-3169.	2.0	10
124	Impact of treatment regimen on acute care use during and after adjuvant chemotherapy for early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 515-525.	1.1	9
125	Childbirth after adolescent and young adult cancer: a population-based study. <i>Journal of Cancer Survivorship</i> , 2018, 12, 592-600.	1.5	9
126	Management of chemotherapy-induced alopecia (CIA): A comprehensive review and future directions. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 156, 103093.	2.0	9

#	ARTICLE	IF	CITATIONS
127	Optimal delivery of male breast cancer follow-up care: improving outcomes. <i>Breast Cancer: Targets and Therapy</i> , 2015, 7, 371.	1.0	8
128	Patient-reported outcomes of catheter-based accelerated partial breast brachytherapy and whole breast irradiation, a single institution experience. <i>Breast Cancer Research and Treatment</i> , 2018, 169, 189-196.	1.1	8
129	Building a Cardio-Onco-Hematology Program. <i>Current Oncology Reports</i> , 2018, 20, 81.	1.8	8
130	Real-World Experiences With Yoga on Cancer-Related Symptoms in Women With Breast Cancer. <i>Global Advances in Health and Medicine</i> , 2021, 10, 216495612098414.	0.7	8
131	Coverage Evaluation of CTCAE for Capturing the Immune-related Adverse Events Leveraging Text Mining Technologies. <i>AMIA Summits on Translational Science Proceedings</i> , 2019, 2019, 771-778.	0.4	8
132	Long-term antimüllerian hormone patterns differ by cancer treatment exposures in young breast cancer survivors. <i>Fertility and Sterility</i> , 2022, 117, 1047-1056.	0.5	8
133	Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. <i>Npj Breast Cancer</i> , 2022, 8, 18.	2.3	8
134	Management of Potential Long-Term Toxicities in Breast Cancer Patients. <i>Current Breast Cancer Reports</i> , 2016, 8, 183-192.	0.5	7
135	Regimen-Specific Rates of Chemotherapy-Related Amenorrhea in Breast Cancer Survivors. <i>JNCI Cancer Spectrum</i> , 2019, 3, .	1.4	7
136	Arm Morbidity After Local Therapy for Young Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2021, 28, 6071-6082.	0.7	7
137	Cancer Survivorship Care: An Opportunity to Revisit Cancer Genetics. <i>Journal of Clinical Oncology</i> , 2016, 34, 539-541.	0.8	6
138	Cardiovascular Concerns in BRCA1 and BRCA2 Mutation Carriers. <i>Current Treatment Options in Cardiovascular Medicine</i> , 2018, 20, 18.	0.4	6
139	Lifestyle Factors Can Lead to Multiple Cancers Over a Lifetime—Here We Go Again. <i>JAMA Oncology</i> , 2021, 7, 505.	3.4	6
140	Tumor phenotype and concordance in synchronous bilateral breast cancer in young women. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 815-821.	1.1	6
141	Detecting and Filtering Immune-Related Adverse Events Signal Based on Text Mining and Observational Health Data Sciences and Informatics Common Data Model: Framework Development Study. <i>JMIR Medical Informatics</i> , 2020, 8, e17353.	1.3	6
142	Psychosocial issues and quality of life of parenting partners of young women with breast cancer. <i>Supportive Care in Cancer</i> , 2022, 30, 4265-4274.	1.0	6
143	Upper Digestive Disease App for Electronic Patient-Reported Outcomes: A Mixed Methods Pilot Study. <i>Annals of Thoracic Surgery</i> , 2022, 114, 1142-1151.	0.7	6
144	Accuracy of self-reported cancer treatment data in young breast cancer survivors. <i>Journal of Patient-Reported Outcomes</i> , 2019, 3, 24.	0.9	5

#	ARTICLE	IF	CITATIONS
145	Amenorrhea after lung cancer treatment. <i>Menopause</i> , 2019, 26, 306-310.	0.8	5
146	Antimullerian Hormone as a Serum Biomarker for Risk of Chemotherapy-Induced Amenorrhea. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1105-1108.	3.0	5
147	Real-world experiences with acupuncture among breast cancer survivors: a cross-sectional survey study. <i>Supportive Care in Cancer</i> , 2020, 28, 5833-5838.	1.0	5
148	CYP3A7*1C allele: linking premenopausal oestrone and progesterone levels with risk of hormone receptor-positive breast cancers. <i>British Journal of Cancer</i> , 2021, 124, 842-854.	2.9	5
149	Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group. <i>Annals of Surgical Oncology</i> , 2021, 28, 8118-8127.	0.7	5
150	N-Terminal Pro Brain Natriuretic Peptide, sST2, and Galectin-3 Levels in Breast Cancer Survivors. <i>Journal of Clinical Medicine</i> , 2021, 10, 3313.	1.0	5
151	Evaluation of significant genome-wide association studies risk SNPs in young breast cancer patients. <i>PLoS ONE</i> , 2019, 14, e0216997.	1.1	4
152	Patient-reported outcomes in the Translational Breast Cancer Research Consortium. <i>Cancer</i> , 2020, 126, 922-930.	2.0	4
153	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
154	Impact of Addition of Carboplatin AUC ≥ 4 to Antiemetic Guidelines for Triple Antiemetic Prophylaxis: A Gap in Quality of Care, Guideline Adoption, and Avoiding Acute Care. <i>JCO Oncology Practice</i> , 2020, 16, e132-e138.	1.4	3
155	Safety, efficacy, and tolerability of systemic therapies in male breast cancer: are there sex-specific differences?. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 923-926.	1.0	3
156	Genetic Variations and Health-Related Quality of Life (HRQOL): A Genome-Wide Study Approach. <i>Cancers</i> , 2021, 13, 716.	1.7	3
157	Atrial Fibrillation and Cancer. <i>JACC: CardioOncology</i> , 2021, 3, 233-235.	1.7	3
158	Breast cancer in young women: clinical decision-making in the face of uncertainty. <i>Oncology</i> , 2009, 23, 474, 477.	0.4	3
159	Late Breast Cancer Survivorship: Side Effects and Care Recommendations. <i>Journal of Clinical Oncology</i> , 2022, 40, 1604-1610.	0.8	3
160	Smart Technology and Endocrine Therapy Adherence. <i>Journal of Clinical Oncology</i> , 2020, 38, 2117-2118.	0.8	2
161	A practical guide to endocrine therapy in the management of estrogen receptor-positive male breast cancer. <i>Breast Cancer Management</i> , 2021, 10, BMT59.	0.2	2
162	Receptivity to a Nurse-Led Symptom Management Intervention Among Highly Symptomatic Patients With Cancer. <i>Journal of the National Cancer Institute</i> , 2022, 114, 458-466.	3.0	2

#	ARTICLE	IF	CITATIONS
163	Integrating Electronic Health Record Data into the ADEpedia-on-OHDSI Platform for Improved Signal Detection: A Case Study of Immune-related Adverse Events. AMIA Summits on Translational Science Proceedings, 2020, 2020, 710-719.	0.4	2
164	Genome-wide interaction analysis of menopausal hormone therapy use and breast cancer risk among 62,370 women. Scientific Reports, 2022, 12, 6199.	1.6	2
165	Fit for Chemo: Nerves May Thank You. Journal of the National Cancer Institute, 2017, 109, djw208.	3.0	1
166	Breast Cancer Survivorship Care Variations Between Adjuvant Chemotherapy Regimens. Clinical Breast Cancer, 2018, 18, e513-e520.	1.1	1
167	What Can We Learn From Menstrual Patterns After Treatment for HER2-Positive Breast Cancer?. Journal of the National Cancer Institute, 2019, 111, 9-10.	3.0	1
168	Reply to On the proportion of male breast cancer among all breast cancers. Cancer, 2020, 126, 2034-2035.	2.0	1
169	Hot flash clinical trial baseline measurements: how long is needed?. BMJ Supportive and Palliative Care, 2023, 13, e1110-e1116.	0.8	1
170	Surveillance mammography after treatment for male breast cancer. Breast Cancer Research and Treatment, 2022, 194, 693-698.	1.1	1
171	Towards defining morphologic parameters of normal parous and nulliparous breast tissues by artificial intelligence. Breast Cancer Research, 2022, 24, .	2.2	1
172	Factors influencing treatment adherence and discontinuation in women with breast cancer. Breast Cancer Management, 2015, 4, 25-31.	0.2	0
173	Management of Menopause in the Breast Cancer Patient. , 2018, , 1024-1030.e4.		0
174	In Reply to Hannoun-Levi and Hannoun. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1177-1179.	0.4	0
175	We need to educate young lung cancer patients about menopause risk. Lung Cancer Management, 2019, 8, LMT08.	1.5	0
176	Common Considerations in Male Breast Cancer Survivors. , 2021, , 319-328.		0
177	ASO Visual Abstract: Secondary Breast Cancer Sociodemographic Characteristics and Survival by Age Group. Annals of Surgical Oncology, 2021, 28, 555-556.	0.7	0
178	Optimizing endocrine therapy in premenopausal ER-positive breast cancer patients. Oncology, 2009, 23, 34, 40.	0.4	0
179	Challenges and Opportunities of Epidemiological Studies to Reduce the Burden of Cancers in Young Adults. Current Epidemiology Reports, 0, , 1.	1.1	0